hrp0084pl5 | Ontogeny of FGF21 in the human: Implications for metabolic health | ESPE2015

Ontogeny of FGF21 in the Human: Implications for Metabolic Health

Villarroya Francesc

Background: FGF21 is a hormonal factor with powerful anti-diabetic and anti-obesity properties in adults\. Studies in rodent models indicated that hepatic FGF21 expression and blood FGF21 levels are strongly induced after birth in response to fat provided by milk ingestion. Moreover, preliminary data indicate that FGF21 is present in maternal milk.Objective and hypotheses: Our objective is to determine, using human samples and pre-clinical experimental m...

hrp0084wg4.1 | Obesity | ESPE2015

The Endocrine Role of Brown Adipose Tissue

Villarroya Francesc

Background: The endocrine role of white adipose tissue (WAT), as a site of release of the so-called adipokines, has been recognized for long. Brown adipose tissue (BAT) is the main site of adaptive thermogenesis in mammals, especially relevant in neonates and early infancy. The amount and activity of BAT are associated with a healthy metabolic profile and protection against obesity, type II diabetes and hyperlipidemia. This biological role of BAT is traditionally attributed to...

hrp0089p2-p150 | Fat, Metabolism and Obesity P2 | ESPE2018

Brown Adipose Tissue in Prepubertal Children: Associations with Sex and With the Sequence of Prenatal Growth Restraint and Postnatal Catch-up

Malpique Rita , Gallego-Escuredo Jose Miguel , Sebastiani Giorgia , Villarroya Joan , Lopez-Bermejo Abel , de Zegher Francis , Villarroya Francesc , Ibanez Lourdes

Background/objectives: Individuals born small-for-gestational age (SGA), especially those who experience postnatal catch-up growth, are at increased risk for developing endocrine-metabolic abnormalities before puberty. In adults, brown adipose tissue (BAT) has been associated with protection against metabolic disorders, such as obesity, type 2 diabetes and dyslipidaemia. Here, we assessed for the first time whether BAT activation differs between prepubertal children born SGA o...

hrp0097t14 | Section | ESPE2023

Circulating Progranulin in Human Infants: Relation to Prenatal Growth and Early Postnatal Nutrition

Díaz Marta , Mestres-Arenas Alberto , López-Bermejo Abel , de Zegher Francis , Villarroya Francesc , Ibáñez Lourdes

Background: Progranulin (PGRN) displays pleiotropic biological functions including on early embryogenesis, cell proliferation, lysosomal or neuronal functioning and wound repair, and has been proposed as a biomarker for metabolic diseases. Increased PGRN levels have been reported in type 2 diabetes, nonalcoholic fatty liver disease and in preeclampsia associated to placental dysfunction. However, the ontogeny of PGRN concentrations and the potential value of P...

hrp0095t6 | Section | ESPE2022

Circulating GDF15 Concentrations in Girls with Low Birth Weight and Precocious Pubarche: Effects of Prolonged Metformin Treatment

Díaz Marta , Carreras-Badosa Gemma , Bassols Judit , de Zegher Francis , López- Bermejo Abel , Villarroya Francesc , Ibáñez Lourdes

Background: Low birth weight (LBW) followed by a rapid postnatal catch-up in weight predisposes individuals to a central distribution of body fat, which is reverted by metformin. Growth-and-differentiation-factor-15 (GDF15) plays an important role in the regulation of energy homeostasis, reducing food intake and lowering body weight. We aimed to assess whether GDF15 concentrations are raised by long-term metformin treatment in LBW/catch-up girls with precociou...

hrp0092fc4.3 | Fat Metabolism and Obesity Session | ESPE2019

Circulating Growth-and-Differentiation Factor-15 in Early Life: Relation to Prenatal and Postnatal Size

Díaz Marta , Campderrós Laura , López-Bermejo Abel , de Zegher Francis , Villarroya Francesc , Ibáñez Lourdes

Background: Growth-and-differentiation factor-15 (GDF15) is a regulator of energy homeostasis, and is used as biomarker of several pathological states.Objectives: To assess longitudinally GDF15 concentrations in a cohort of infants born either appropriate- (AGA, n=70) or small-for-gestational-age (SGA, n=33), the latter known to be at increased risk for central adiposity and metabolic alteration...

hrp0082p2-d2-378 | Fat Metabolism & Obesity (1) | ESPE2014

Circulating Concentrations of Fibroblast Growth Factor 21 are Undetectable in Human Infants at Term Birth and Surge within Hours After Birth

Sanchez-Infantes David , Gallego-Escudero Jose Miguel , Cereijo Ruben , Diaz Marta , Aragones Gemma , Lopez-Bermejo Abel , de Zegher Francis , Villarroya Francesc , Ibanez Lourdes

Background: In rodents, fibroblast growth factor 21 (FGF21), an endocrine member of the FGF family, is mainly produced in the liver and promotes glucose oxidation in several tissues; the circulating concentrations of FGF21 rise shortly after birth. In the human, the ontogeny of circulating FGF21 is essentially unknown.Objective and hypotheses: To assess whether there is also a neonatal surge of circulating FGF21 concen...

hrp0097p1-253 | Fat, Metabolism and Obesity | ESPE2023

Effect of growth hormone on thermogenic and endocrine activity of brown adipose tissue and on the lipidome of children born small for gestational age

Murillo-Vallés Marta , González-López Lorena , Valls-Llussà Aina , González-Riaño Carolina , Cereijo-Tellez Rubén , Jimenez-Pavón David , Barbas Coral , Villarroya Francesc , Sánchez-Infantes David

Introduction: Brown adipose tissue (BAT) secretes molecules capable of modulating systemic metabolism. Growth hormone (GH) has hyperglycemic action, produces lipolysis and increases muscle mass. However, there are no human studies on its effect on the BAT and lipidome.Aim: To evaluate the effect of GH on BAT and lipidome in small for gestational age (SGA) patients and its relationship with adherence to treatment.<p c...